healthtech-company-huma-partners-with-bayer-to-provide-precision-treatment-for-lung-cancer

Healthtech Company Huma Partners with Bayer to Provide Precision Treatment for Lung Cancer

Huma, a leading healthtech company, is partnering with life sciences company Bayer to advance diagnosis for certain types of lung cancer by utilizing artificial intelligence and machine learning to achieve more precise readings of computer tomography (CT) scans.

The collaboration aims to provide improved methods of determining the specific form of cancer a patient has from CT scans by distinguishing different forms of non-small-cell lung carcinomas (NSCLCs). This would allow specialists to begin more appropriate and timely treatment.

Current methods of characterizing specific cancer types include undergoing a series of tests, which are often invasive, costly, and time consuming. It is therefore essential to find new ways to ensure the right patients are being treated at the right time with the right medication. Huma and Bayer are implementing machine learning to help categorize and segment patient subtypes.

The first step will include training an AI to spot correlations in molecular and imaging assessments such as “ground glass opacity” that can differentiate lung cancer types. The team will then create, train, and test models that can accurately diagnose the different types of lung cancers.

Dan Vahdat, CEO and Founder of Huma, said: “We have shown we can use machine learning to predict an individual’s risk of depression, anxiety, cardiac events and the impact of being infected by COVID-19, and we hope this work in cancer will be a new field for us. However, as always, we will publish any significant developments in peer-reviewed journals. We know the importance of evidence-based, rigorous innovation and, by doing it the right way, we can more rapidly make meaningful, impactful changes and help people live longer, fuller lives.”

“We want to start by providing more personalised care for people with non-small cell lung cancer. In the future, our vision is to include other cancers and even other therapeutic areas such as rare diseases. We want to broaden our existing smartphone platform to combine imaging, digital phenotyping, and genomics with the real-world, real-time data from patients that we already collect. We want to take therapies from bench to bedside to breakfast table.”

Robert LaCaze, Head of Oncology, Pharmaceuticals Division of Bayer, added:Rather than treating all lung cancer patients with standardized regimens, precision medicine can allow physicians to prescribe medicines tailored to the tumor’s specific oncogenic driver. Our collaboration leverages Huma’s proven expertise in Machine Learning and Bayer’s vast capabilities in Oncology and Medical Imaging to help accelerate the identification of those patients with certain types of non-small cell lung cancer who can most benefit from these tailored treatments.

Leaps by Bayer, the impact investment arm of Bayer, has been a Series B (2019) and Series C (2021) investor into Huma. Huma and Bayer plan to begin work on this project immediately.

Roboticulized digests/handpicks the latest news about the artificial intelligence/machine learning industry and serves them to you daily. We provide you with the latest news and press releases straight from the AI/ML industry.
Hipther

FREE
VIEW